Immunologic Research

, Volume 56, Issue 1, pp 131–142

C-reactive protein and the biology of disease

Article

Abstract

The C-reactive protein (CRP) is a plasma protein of hepatic origin, belonging to pentraxin family and forms a major component of any inflammatory reaction. A key component of the innate immunity pathway, the concentration of CRP may rapidly increase to levels more than 1,000-folds above normal values as a consequence to tissue injury or infection. Although functioning as a classical mediator of innate immunity, it functions via interaction of components of both humoral and cellular effector systems of inflammation. Initially considered as an acute-phase marker in tissue injury, infection and inflammation, it now has a distinct status of a disease marker in cardiovascular diseases and is well known of its clinical and pathological significance. The present torrent of studies in a large number of diseases and associated conditions has highly elucidated the role of CRP as a therapeutic and research reagent. In this review, we focus our attention to role of CRP in health and disease. The future prospect of this review lies in the applicability of CRP as a molecule in understanding and monitoring of the biology of disease.

Keywords

C-reactive protein Disease Inflammation 

References

  1. 1.
    Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 1930;52:561–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Macleod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. II. Isolation and properties of the reactive protein. J Exp Med. 1941;73:183–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Abernethy TJ, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. 1. Distribution of the reactive protein in patient’s sera and the effect of calcium on the flocculation reaction with C polysaccharide of Pneumococcus. J Exp Med. 1941;73:173–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406–18.PubMedCrossRefGoogle Scholar
  5. 5.
    Li YP, Mold C, Du Clos TW. Sublytic complement attack exposes C-reactive protein binding sites on cell membranes. J Immunol. 1994;152:2995–3005.PubMedGoogle Scholar
  6. 6.
    Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189–97.PubMedCrossRefGoogle Scholar
  7. 7.
    Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17:1019–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Du Clos TW. C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol. 1989;143:2553–9.PubMedGoogle Scholar
  9. 9.
    Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of C-reactive protein to histones and chromatin. J Immunol. 1988;141:4266–70.PubMedGoogle Scholar
  10. 10.
    Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.PubMedCrossRefGoogle Scholar
  11. 11.
    Pepys MB, Dash AC, Fletcher TC, Richardson N, Munn EA. Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature. 1978;273:168–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Robey FA, Liu TY. Limulin: a C-reactive protein from Limulus polyphemus. J Biol Chem. 1981;256:969–75.PubMedGoogle Scholar
  13. 13.
    Olafsen JA. Role of lectins (C-reactive protein) in defense of marine bivalves against bacteria. Adv Exp Med Biol. 1995;371A:343–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Nagpurkar A, Mookerjea S. A novel phosphorylcholine-binding protein from rat serum and its effect on heparin-lipoprotein complex formation in the presence of calcium. J Biol Chem. 1981;256:7440–6.PubMedGoogle Scholar
  15. 15.
    De Beer FC, Pepys MB. Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods. 1982;50:17–31.PubMedCrossRefGoogle Scholar
  16. 16.
    De Beer FC, Shine B, Pepys MB. Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. Clin Exp Immunol. 1982;50:231–7.PubMedGoogle Scholar
  17. 17.
    Mandal C, Sinha S, Mandal C. Lectin like properties and differential sugar binding characteristics of C-reactive proteins purified from sera of normal and pollutant induced Labeo rohita. Glycoconj J. 1999;16:741–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Sinha S, Mandal C. Microheterogeneity of C-reactive protein in the sera of fish Labeo rohita induced by metal pollutants. Biochem Biophys Res Commun. 1996;226:681–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Paul I, Mandal C, Allen AK, Mandal C. Glycosylated molecular variants of C-reactive proteins from the major carp Catla catla in fresh and polluted aquatic environments. Glycoconj J. 2001;18:547–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Kushner I. The acute phase response: an overview. Methods Enzymol. 1988;163:373–83.PubMedCrossRefGoogle Scholar
  21. 21.
    McCarty M. The occurrence during acute infections of a protein not normally present in the blood: IV. Crystallization of the C-reactive protein. J Exp Med. 1947;85:491–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med. 1966;123:365–78.PubMedCrossRefGoogle Scholar
  23. 23.
    Dong Q, Wright JR. Expression of C-reactive protein by alveolar macrophages. J Immunol. 1996;156:4815–20.PubMedGoogle Scholar
  24. 24.
    Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001;69:1747–54.PubMedCrossRefGoogle Scholar
  26. 26.
    Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003;33:152–61.PubMedCrossRefGoogle Scholar
  27. 27.
    Hutchinson WL, Noble GE, Hawkins PN, Pepys MB. The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest. 1994;94:1390–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW. C-reactive protein binds to FcγRI in transfected COS cells. J Immunol. 1995;155:2185–93.PubMedGoogle Scholar
  29. 29.
    Das T, Sen A, Kempf T, Pramanik SR, Mandal C, Mandal C. Induction of glycosylation in human C-reactive protein under different pathological conditions. Biochem J. 2003;373:345–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370–1.PubMedCrossRefGoogle Scholar
  31. 31.
    Ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol. 1990;17:1642–8.PubMedGoogle Scholar
  32. 32.
    Das UN. Is obesity an inflammatory condition? Nutrition. 2001;17:953–66.PubMedCrossRefGoogle Scholar
  33. 33.
    Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105:564–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Chandrashekara S, Sachin S. Measures in rheumatoid arthritis: are we measuring too many parameters. Int J Rheum Dis. 2012;15:239–48.PubMedCrossRefGoogle Scholar
  36. 36.
    Galeazzi M, Morozzi G, Veronesi M, Ronconi S, Magi B, Bini L, et al. Usefulness of the determination of C reactive protein and other acute phase proteins in rheumatoid arthritis. Recenti Prog Med. 1995;86:456–62.PubMedGoogle Scholar
  37. 37.
    Wu JF, Yang YH, Wang LC, Lee JH, Shen EY, Chiang BL. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in juvenile rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:782–5.PubMedGoogle Scholar
  38. 38.
    Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 1994;24:91–104.PubMedCrossRefGoogle Scholar
  39. 39.
    Vogt B, Führnrohr B, Müller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity. 2007;40:295–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum. 2008;59:1814–20.PubMedCrossRefGoogle Scholar
  41. 41.
    Rezaieyazdi Z, Sahebari M, Hatef MR, Abbasi B, Rafatpanah H, Afshari JT, et al. Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus? Lupus. 2011;20:1494–500.PubMedCrossRefGoogle Scholar
  42. 42.
    Olson RE. Atherogenesis in children: implications for the prevention of atherosclerosis. Adv Pediatr. 2000;47:55–78.PubMedGoogle Scholar
  43. 43.
    Pereira IA, Borba EF. The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis. Swiss Med Wkly. 2008;138:534–9.PubMedGoogle Scholar
  44. 44.
    Danesh J, Pepys MB. C-reactive protein in healthy and in sick populations. Eur Heart J. 2000;21:1564–5.PubMedCrossRefGoogle Scholar
  45. 45.
    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.PubMedGoogle Scholar
  46. 46.
    Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of stain therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–65.PubMedCrossRefGoogle Scholar
  47. 47.
    Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation. 1999;100:230–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.Google Scholar
  49. 49.
    Emerging Risk Factor Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20.PubMedCrossRefGoogle Scholar
  50. 50.
    Kushner I, Rakita L, Kaplan MH. Studies of acute phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest. 1963;42:286–92.PubMedCrossRefGoogle Scholar
  51. 51.
    Kushner I, Kaplan MH. Antigenic analysis of extracts of human heart tissue: cardiac antigens with limited distribution in other organs. J Immunol. 1967;99:526–33.PubMedGoogle Scholar
  52. 52.
    Kushner I. C-reactive protein and atherosclerosis. Science. 2002;297:520–1.PubMedCrossRefGoogle Scholar
  53. 53.
    Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733–9.PubMedCrossRefGoogle Scholar
  54. 54.
    de Ferranti S, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta. 2002;317:1–15.PubMedCrossRefGoogle Scholar
  55. 55.
    Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635–41.PubMedCrossRefGoogle Scholar
  56. 56.
    Tanigaki K, Vongpatanasin W, Barrera JA, Atochin DN, Huang PL, Bonvini E, et al. C-reactive protein causes insulin resistance in mice through Fcγ receptor IIB-mediated inhibition of skeletal muscle glucose delivery. Diabetes. 15 Oct 2012. [in press].Google Scholar
  57. 57.
    Mugabo Y, Li L, Renier G. The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Curr Diabetes Rev. 2010;6:27–34.PubMedCrossRefGoogle Scholar
  58. 58.
    King DE, Mainous AG 3rd, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26:1535–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.PubMedCrossRefGoogle Scholar
  60. 60.
    Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13:R55.PubMedCrossRefGoogle Scholar
  62. 62.
    Helzlsouer KJ, Erlinger TP, Platz EA. Creactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur J Cancer. 2006;42:704–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155–70.PubMedCrossRefGoogle Scholar
  64. 64.
    Ansar W, Bandyopadhyay SM, Chowdhury S, Habib SH, Mandal C. Role of C-reactive protein in complement mediated hemolysis in malaria. Glyconj J. 2006;23:233–40.CrossRefGoogle Scholar
  65. 65.
    Dongho Dongmo FF, Ngono Ngane RA, Gouado I, Pankoui Mfonkeu JB, Mbackop Kwemba V, et al. Predictors of childhood severe malaria in a densely populated area: Douala, Cameroon. Afr J Biotechnol. 2011;10:6319–24.Google Scholar
  66. 66.
    Nahrevanian H, Gholizadeh J, Farahmand M, Assmar M. Patterns of co-association of C-reactive protein and nitric oxide in malaria in endemic areas of Iran. Mem Inst Oswaldo Cruz. 2008;103:39–44.PubMedCrossRefGoogle Scholar
  67. 67.
    Bourée P, Botterel F, Lançon A. Comparative study VS-CRP in malaria. Mal. Inf. Dis. Afr. 2000;2–3.Google Scholar
  68. 68.
    Kremsner PG, Winkler S, Wildling E, Prada J, Bienzlz U, Graninger W, Nüssler AK. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitogical and clinical cure in Plasmodium falciparum malaria. Trans R Trop Med Hyg. 1996;90:44–7.CrossRefGoogle Scholar
  69. 69.
    Paul R, Sinha PK, Banerjee AK, Raychaudhuri P, Mondal J. Study of C reactive protein as a prognostic marker in malaria from Eastern India. Adv Biomed Res. 2012;1:1–9.CrossRefGoogle Scholar
  70. 70.
    Gjørup IE, Vestergaard LS, Møller K, Rønn AM, Bygbjerg IC. Laboratory indicators of the diagnosis and course of imported malaria. Scand J Infect Dis. 2007;39:707–13.PubMedCrossRefGoogle Scholar
  71. 71.
    Jakobsen PH, Mckay V, Jie RN, Olaleye BO, D’alessandro U, Zhang GH, et al. Decreased antitoxic activities among children with clinical episodes of malaria. Infect Immun. 1998;66:1654–9.PubMedGoogle Scholar
  72. 72.
    Ansar W, Mandal C, Habib Sk, Roy S, Mandal C. Unraveling the C-reactive protein complement-cascade in destruction of red blood cells: potential pathological implications in Plasmodium falciparum malaria. Cell Physiol Biochem. 2009;23:169–75.CrossRefGoogle Scholar
  73. 73.
    Culley FJ, Harris RA, Kaye PM, McAdam KP, Raynes JG. C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol. 1996;156:4691–6.PubMedGoogle Scholar
  74. 74.
    Culley FJ, Thomson M, Raynes JG. C-reactive protein increases C3 deposition on Leishmania donovani promastigotes in human serum. Biochem Soc Trans. 1997;25:286S.PubMedGoogle Scholar
  75. 75.
    Culley FJ, Bodman-Smith KB, Ferguson MA, Nikolaev AV, Shantilal N, Raynes JG. C-reactive protein binds to phosphorylated carbohydrates. Glycobiology. 2000;10:59–65.PubMedCrossRefGoogle Scholar
  76. 76.
    Bodman-Smith KB, Mbuchi M, Culley FJ, Bates PA, Raynes JG. C-reactive protein-mediated phagocytosis of Leishmania donovani promastigotes does not alter parasite survival or macrophage responses. Parasite Immunol. 2002;24:447–54.PubMedCrossRefGoogle Scholar
  77. 77.
    Bee A, Culley FJ, Alkhalife IS, Bodman-Smith KB, Raynes JG, Bates PA. Transformation of Leishmania mexicana metacyclic promastigotes to amastigote-like forms mediated by binding of human C-reactive protein. Parasitology. 2001;122:521–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Ansari NA, Sharma P, Salotra P. Circulating nitric oxide and C-reactive protein levels in Indian kala azar patients: correlation with clinical outcome. Clin Immunol. 2007;122:343–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Ansar W, Mukhopadhyay S, Habib SK, Basu S, Saha B, Sen AK, et al. Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis. Glycoconj J. 2009;26:1151–69.PubMedCrossRefGoogle Scholar
  80. 80.
    Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM. 2003;96:793–807.PubMedCrossRefGoogle Scholar
  81. 81.
    Gasim S, Theander TG, ElHassan AM. High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. Acta Trop. 2000;75:35–8.PubMedCrossRefGoogle Scholar
  82. 82.
    de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982;47:239–43.PubMedCrossRefGoogle Scholar
  83. 83.
    Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J. 2011;162:597–605.PubMedCrossRefGoogle Scholar
  84. 84.
    Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212.PubMedCrossRefGoogle Scholar
  85. 85.
    Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, et al. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods. 2012;384:92–102.PubMedCrossRefGoogle Scholar
  86. 86.
    Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure. 1999;7:169–77.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Post Graduate DepartmentAsutosh CollegeKolkataIndia
  2. 2.School of Biological Sciences, National Institute of Science, Education and Research, (NISER)BhubaneswarIndia

Personalised recommendations